Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). WAVE Life Sciences's share price for the quarter that ended in Mar. 2026 was €5.5. WAVE Life Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 192.34 Mil. Therefore, WAVE Life Sciences's market cap for the quarter that ended in Mar. 2026 was €1,057.86 Mil.
WAVE Life Sciences's quarterly market cap
increased
from Sep. 2025 (€921.66 Mil) to Dec. 2025 (€2,777.37 Mil) but then
declined
from Dec. 2025 (€2,777.37 Mil) to Mar. 2026 (€1,057.86 Mil).
WAVE Life Sciences's annual market cap
increased
from Dec. 2023 (€541.00 Mil) to Dec. 2024 (€1,867.05 Mil) and
increased
from Dec. 2024 (€1,867.05 Mil) to Dec. 2025 (€2,777.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. WAVE Life Sciences's Enterprise Value for Today is €593.22 Mil.
WAVE Life Sciences (FRA:1U5) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
WAVE Life Sciences Market Cap Related Terms
WAVE Life Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1U5 vs CGEM, LXRX, XNCR: Market Cap Comparison
For the Biotechnology subindustry, WAVE Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
WAVE Life Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (FRA:1U5) has a Market Cap of €1,057.64 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on WAVE Life Sciences and its competitors. According to the industry distribution chart, WAVE Life Sciences ranks #262 out of 1423 companies in the Biotechnology industry, placing it in the top 18.4%.
Is WAVE Life Sciences' Market Cap too high?
WAVE Life Sciences' current Market Cap is €1,057.64 Mil. Based on the distribution chart, WAVE Life Sciences ranks #262 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' Market Cap compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #262 out of 1423 companies for Market Cap. This places WAVE Life Sciences in the top 18% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current Market Cap is €1,057.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €5.20 — trading 42.9% above its estimated fair value. The current Market Cap is €1,057.64 Mil. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current Market Cap is €1,057.64 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of €5.20 is trading 42.9% above its estimated GF Value™ of €3.64.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:1U5:
Market Cap: €1,057.64 Mil
GF Value™: €3.64 vs. price of €5.20 (42.9% above fair value)
No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for FRA:1U5
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1U5 has been successfully added to your 
